<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985736</url>
  </required_header>
  <id_info>
    <org_study_id>JB-02</org_study_id>
    <nct_id>NCT02985736</nct_id>
  </id_info>
  <brief_title>Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray</brief_title>
  <official_title>An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily
      BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive Topicort® twcie daily (BID) for 4 weeks. After week 4 patients will
      receive Topicort® twice weekly (on consecutive days) for 12 weeks, Patients will treat other
      body areas affected by plaque psoriasis with Topicort® during the study period (excludes
      face, groin, axilla)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">January 27, 2017</completion_date>
  <primary_completion_date type="Actual">January 27, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment (scalp only)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Scalp psoriasis severity scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Scalp Severity Index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Scalp psoriasis severity scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scalp Surface Area</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measures % of scalp affected with psoriasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body surface area multiplied by physician's global assessement</measure>
    <time_frame>16 weeks</time_frame>
    <description>measures psoriasis severity improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>scalpdex questionnaire</measure>
    <time_frame>16 weeks</time_frame>
    <description>patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analog scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>measures subject assessment of pain</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topicort Topical Spray</intervention_name>
    <arm_group_label>open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults ≥ 18 years of age.

          2. Diagnosis of chronic plaque-type scalp psoriasis.

          3. IGA of mild or greater (scalp only) determined at screening

          4. Scalp surface area of 30% or greater determined at screening

          5. Able to give written informed consent prior to performance of any study related
             procedures.

          6. Females of childbearing potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. FCBP who engage in activity in which conception is possible
             must use one of the approved contraceptive options: hormonal contraception;
             intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female
             condom, diaphragm with spermicide, cervical cap with spermicide, or contraceptive
             sponge with spermicide.

          7. Subject must be in general good health (except for psoriasis) as judged by the
             Investigator, based on medical history, physical examination.

        Exclusion Criteria:

          1. &lt;30% scalp surface area

          2. Scalp Investigator global assessment (IGA) clear or almost clear at time of screening

          3. Any condition, which would place the subject at unacceptable risk if he/she were to
             participate in the study.

          4. Pregnant or breast feeding, or considering becoming pregnant during the study.

          5. Use of any investigational drug within 4 weeks prior to randomization, or within 5
             pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

          6. Use of oral systemic medications for the treatment of psoriasis within 4 weeks
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin,
             apremilast and cyclosporine).

          7. Use of ustekinumab and/or anti-IL-17 (interleukin 17) biologic therapy within 24 weeks
             or other experimental or commercially available biologic immune modulator(s) within 12
             weeks prior to the first IP dose.

          8. Patient used other topical therapies to treat within 2 weeks of the Baseline Visit
             (not including permitted topical therapy for face, groin and axilla).

          9. Patient received ultraviolet B, UVB phototherapy within 2 weeks of Baseline.

         10. Patient received psoralen and Ultraviolet A, PUVA phototherapy within 4 weeks of
             Baseline.

         11. Patient has a known hypersensitivity to the excipients of Topicort Spray® as stated in
             the label.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desoximetasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 6, 2018</submitted>
    <returned>May 4, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

